For years, the scientific understanding of cellular organization has been relatively straightforward: the mitochondria act as the power plant, the cytoplasm serves as the factory floor, and the nucleus functions as the vault for genetic information. However, new research published in Nature Communications by the Centre for Genomic Regulation (CRG) suggests these boundaries are far more porous than previously thought.
The study provides the first global evidence that the nucleus is crowded with metabolic enzymes. By analyzing 44 cancer cell lines and 10 healthy tissue types, the researchers discovered that approximately seven percent of all proteins attached to chromatin — the complex of DNA and proteins — are actually metabolic enzymes. These findings have led the authors to propose that cells possess a "nuclear metabolic fingerprint" that is specific to both the tissue type and the disease state.
Specificity across cancer types
The distribution of these enzymes is not a one-size-fits-all phenomenon. The team observed that breast cancer cells, for example, show significantly higher nuclear levels of energy-producing enzymes compared to lung cancer cells. This tissue-specific metabolism suggests that different tumors may adopt unique survival strategies by relocating their metabolic machinery directly onto the DNA.
This discovery challenges the traditional separation of metabolism and genome regulation. According to Savvas Kourtis, the study's first author, treating these as two separate universes may have limited our understanding of how cancer survives. "Our work suggests they’re talking to each other, and cancer cells might be exploiting these conversations to survive," Kourtis noted in the press release.
Strategic location and drug resistance
One of the most significant implications of the study involves how cancer responds to treatment. Many chemotherapy and radiotherapy protocols rely on creating genotoxic stress — essentially breaking the DNA of cancer cells to stop them from multiplying.
The researchers found that certain enzymes, which synthesize the essential building blocks for DNA repair, gather specifically around chromatin when the genome is damaged. When the enzyme IMPDH2 was forced to stay in the nucleus, it helped maintain genome stability; when confined to the cytoplasm, its role changed entirely. This suggests that the physical location of an enzyme determines its biological impact.
Sara Sdelci, the study’s corresponding author and a researcher at the CRG, believes this localized metabolism could be a missing piece in the puzzle of drug resistance. "Many of these enzymes synthesize essential building blocks of life, and their nuclear localization is associated with DNA repair," Sdelci said. "Their presence in the nucleus may therefore directly shape how cancer cells respond to genotoxic stress, a hallmark of many chemotherapeutic treatments. It’s an entirely new world to explore."
A mechanical mystery
Beyond the therapeutic implications, the discovery presents a fundamental biological question. Many of the metabolic enzymes found inside the nucleus are significantly larger than the known size limits of the nuclear pore — the gateway that controls what enters and exits the nucleus.
The fact that these bulky enzymes are successfully navigating into the nucleus suggests there is a yet-to-be-discovered transport mechanism at work. Identifying how these enzymes bypass standard cellular security could lead to highly precise therapeutic targets. If scientists can learn to block this transport, they might be able to starve the nucleus of the tools it needs to repair itself, making existing cancer treatments far more effective.
